SPECIALTY GUIDELINE MANAGEMENT

ORGOVYX (relugolix)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

- A. <u>FDA-Approved Indications</u> Orgovyx is indicated for the treatment of adult patients with advanced prostate cancer.
- B. <u>Compendial Uses</u> Prostate Cancer

All other indications are considered experimental/investigational and not medically necessary.

II. CRITERIA FOR INITIAL APPROVAL

Prostate Cancer

Authorization of 12 months may be granted for treatment of prostate cancer when used as a single agent.

III. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization who are experiencing clinical benefit to therapy (e.g., maintaining serum testosterone to less than 50ng/dL) and who have not experienced an unacceptable toxicity.

IV. REFERENCES

- 1. Orgovyx [package insert]. Brisbane, CA: Myovant Sciences, Inc; December 2020.
- 2. The NCCN Drugs & Biologics Compendium® © 2021 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed July 6, 2021.

Orgovyx 4411-A SGM P2021 .docx

© 2021 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

